GlobalData on MSN23h
MSD’s WELIREG approved by NMPA to treat VHL disease-associated tumoursThe approval is based on the Phase II LITESPARK-004 trial's objective response rate and median duration of response outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback